Health ❯ Healthcare ❯ Pharmaceuticals ❯ Clinical Trials

Drug Development

Novartis’ Del‑Desiran Misses Phase III and Triggers Large Share Selloff

The result could change investor views on the value of Novartis' $12 billion Avidity acquisition by reducing confidence in its late‑stage neuromuscular bets and prompting a formal data review with regulators.

10 ARTICLES

last mo.

Amylyx’s Avexitide Cuts Moderate‑to‑Severe Post‑Bariatric Hypoglycemia Events 55% in Phase 3

45 ARTICLES

4mo ago

Pfizer’s Once‑Monthly GLP‑1 Shows Strong Weight Loss but Raises Dosing‑Safety Questions

9 ARTICLES

4mo ago

Novo’s Triple-Hormone Obesity Drug UBT251 Hits 19.7% Mean Weight Loss in China Phase 2

8 ARTICLES

8mo ago

Vistagen Faces Federal Securities Class Action After Fasedienol Phase 3 Failure

12 ARTICLES

10mo ago

GLP-1 Boom Hits a Crossroads as States Cut Coverage and Next‑Gen Drugs Advance

5 ARTICLES

10mo ago

Jasper Therapeutics Investors Face Lead Plaintiff Deadline in Securities Class Action

3 ARTICLES

last yr.

Regeneron’s Garetosmab Slashes New Bone Lesions in FOP Phase 3, U.S. Filing Planned This Year